芳香化酶抑制剂对非骨质疏松绝经后乳腺癌患者骨微结构与宏结构的长期影响
本研究为回顾性纵向观察研究,纳入接受芳香化酶抑制剂(AIs)治疗≥3年的非骨质疏松绝经后乳腺癌患者,采用双能X线吸收法连续评估骨密度、腰椎骨小梁评分及髋部几何结构。结果显示AIs长期治疗显著降低骨密度、骨小梁评分及髋部几何参数,作者认为对开始AIs治疗的非骨质疏松乳腺癌患者需早期监测与管理。
要点
- AIs治疗5年时腰椎、股骨颈和全髋骨密度分别较基线下降6.15%、7.12%和6.35%。
- 腰椎骨小梁评分5年时较基线下降2.12%,校正腰椎骨密度后仍显著。
- 髋部几何参数(截面面积、截面惯性矩等)显著下降,屈曲比增加,均P<0.001。
核心结论
- 长期辅助AIs治疗除影响骨密度外,还对乳腺癌患者的骨质量产生负面影响。
- 本研究提示对开始AIs治疗的非骨质疏松乳腺癌患者需要早期监测和管理。
研究设计与样本
- 回顾性纵向观察研究,纳入接受AIs治疗≥3年(T值>-2.5)的非骨质疏松原发性乳腺癌绝经后患者。
- 排除既往接受抗骨质疏松治疗或AIs治疗期间使用双膦酸盐的患者。
- 采用双能X线吸收法连续评估骨密度、腰椎骨小梁评分和髋部几何结构。
主要发现
- 骨密度从基线至5年在腰椎下降6.15%、股骨颈下降7.12%、全髋下降6.35%。
- 腰椎骨小梁评分从基线至5年下降2.12%,校正腰椎骨密度后变化仍显著。
- 腰椎骨密度和骨小梁评分的年丢失分别在治疗3年和1年后减慢,而股骨颈和全髋骨密度在长达4年内相对恒定丢失。
- 截面面积、截面惯性矩、最小颈宽、股骨强度指数和截面模量显著下降,屈曲比在治疗期间增加(均P<0.001),这些变化独立于全髋骨密度。
临床怎么用
- 作者认为,对开始AIs治疗的非骨质疏松乳腺癌患者需要早期监测和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In non-osteoporotic postmenopausal women with breast cancer, aromatase inhibitors (AIs) negatively affected bone mineral density (BMD), lumbar spine trabecular bone score (TBS) as a bone microarchitecture index, and hip geometry as a bone macroarchitecture index. INTRODUCTION: AIs increase the risk of fracture in patients with breast cancer. Therefore, we aimed to evaluate the long-term skeletal effects of AIs in postmenopausal women with primary breast cancer. METHODS: We performed a retrospective longitudinal observational study in non-osteoporotic patients with breast cancer who were treated with AIs for ≥3 years (T-score >-2.5). Patients with previous anti-osteoporosis treatment or those who were given bisphosphonate during AI treatment were excluded from the analysis. We serially assessed BMD, lumbar spine TBS, and hip geometry using dual-energy X-ray absorptiometry. RESULTS: BMD significantly decreased from baseline to 5 years at the lumbar spine (-6.15%), femur neck (-7.12%), and total hip (-6.35%). Lumbar spine TBS also significantly decreased from baseline to 5 years (-2.12%); this change remained significant after adjusting for lumbar spine BMD. The annual loss of lumbar spine BMD and TBS slowed after 3 and 1 year of treatment, respectively, although there was a relatively constant loss of BMD at the femur neck and total hip for up to 4 years. The cross-sectional area, cross-sectional moment of inertia, minimal neck width, femur strength index, and section modulus significantly decreased, although the buckling ratio increased over the treatment period (all P < 0.001); these changes were independent of total hip BMD. CONCLUSIONS: Long-term adjuvant AI treatment negatively influenced bone quality in addition to BMD in patients with breast cancer. This study suggests that early monitoring and management are needed in non-osteoporotic patients with breast cancer who are starting AIs.
引用
- Hong AR, Kim JH, Lee KH, et al. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int. 2017. PMID: 28083668. doi:10.1007/s00198-016-3899-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。